Your browser doesn't support javascript.
loading
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto, Paolo Antonio; Lipson, Evan J; Dummer, Reinhard; Larkin, James; Long, Georgina V; Sanborn, Rachel E; Chiarion-Sileni, Vanna; Dréno, Brigitte; Dalle, Stéphane; Schadendorf, Dirk; Callahan, Margaret K; Nyakas, Marta; Atkinson, Victoria; Gomez-Roca, Carlos Alberto; Yamazaki, Naoya; Tawbi, Hussein A; Sarkis, Naomey; Warad, Deepti; Dolfi, Sonia; Mitra, Priyam; Suryawanshi, Satyendra; Grob, Jean-Jacques.
Afiliação
  • Ascierto PA; Melanoma, Cancer Immunotherapy, and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy.
  • Lipson EJ; Sidney Kimmel Comprehensive Cancer Center, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Dummer R; Department of Dermatology, University of Zurich, Zurich, Switzerland.
  • Larkin J; Medical Oncology, The Institute of Cancer Research, London, London, UK.
  • Long GV; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
  • Sanborn RE; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR.
  • Chiarion-Sileni V; Melanoma Oncology Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padua, Italy.
  • Dréno B; Nantes Université, INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France.
  • Dalle S; Unit of Dermatology, Hospices Civils de Lyon, Cancer Research Center of Lyon, Pierre-Bénite, France.
  • Schadendorf D; Department of Dermatology, University Hospital Essen, and the German Cancer Consortium, Essen, Germany.
  • Callahan MK; Immunotherapeutics Program, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Nyakas M; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Atkinson V; Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, QLD, Australia.
  • Gomez-Roca CA; Department of Medicine & Clinical Research Unit, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
  • Yamazaki N; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Tawbi HA; Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Sarkis N; Relatlimab Clinical Development Melanoma, Bristol Myers Squibb, Princeton, NJ.
  • Warad D; Relatlimab Clinical Development Melanoma, Bristol Myers Squibb, Princeton, NJ.
  • Dolfi S; Translational Medicine, Bristol Myers Squibb, Princeton, NJ.
  • Mitra P; Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ.
  • Suryawanshi S; Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Princeton, NJ.
  • Grob JJ; Dermatology, Aix-Marseille University, CHU Timone, Marseille, France.
J Clin Oncol ; 41(15): 2724-2735, 2023 05 20.
Article em En | MEDLINE | ID: mdl-36780608
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article